KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Oct 29, 2019 $0.347 $0.360 $0.336 $0.340 549 914
Oct 28, 2019 $0.338 $0.349 $0.332 $0.347 291 937
Oct 25, 2019 $0.339 $0.350 $0.330 $0.342 311 352
Oct 24, 2019 $0.350 $0.359 $0.335 $0.338 527 971
Oct 23, 2019 $0.340 $0.355 $0.332 $0.348 225 680
Oct 22, 2019 $0.345 $0.360 $0.325 $0.339 656 775
Oct 21, 2019 $0.374 $0.380 $0.343 $0.344 723 563
Oct 18, 2019 $0.380 $0.404 $0.362 $0.376 1 776 469
Oct 17, 2019 $0.365 $0.380 $0.342 $0.378 1 215 710
Oct 16, 2019 $0.335 $0.363 $0.332 $0.360 1 141 314
Oct 15, 2019 $0.340 $0.349 $0.329 $0.340 905 912
Oct 14, 2019 $0.330 $0.343 $0.330 $0.337 273 280
Oct 11, 2019 $0.337 $0.342 $0.330 $0.330 249 356
Oct 10, 2019 $0.340 $0.349 $0.325 $0.325 377 590
Oct 09, 2019 $0.335 $0.339 $0.325 $0.325 184 920
Oct 08, 2019 $0.349 $0.349 $0.322 $0.322 549 809
Oct 07, 2019 $0.322 $0.367 $0.313 $0.349 1 793 669
Oct 04, 2019 $0.313 $0.325 $0.313 $0.320 181 915
Oct 03, 2019 $0.312 $0.318 $0.305 $0.308 185 086
Oct 02, 2019 $0.318 $0.320 $0.305 $0.312 330 336
Oct 01, 2019 $0.326 $0.333 $0.310 $0.329 703 573
Sep 30, 2019 $0.322 $0.322 $0.313 $0.315 719 421
Sep 27, 2019 $0.322 $0.325 $0.312 $0.317 434 546
Sep 26, 2019 $0.320 $0.327 $0.310 $0.325 448 513
Sep 25, 2019 $0.329 $0.329 $0.305 $0.320 1 089 846
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT